Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
91.5In this multicenter, double-blind randomized clinical trial of 784 adults undergoing elective cardiac surgery, four perioperative doses of dapagliflozin reduced postoperative AKI from 52% to 28% compared with placebo (relative risk 0.54, 95% CI 0.45-0.65; P<.001). Follow-up testing was completed in 99% of participants, and atrial fibrillation and reoperation rates were similar between groups.